Why flu seems to be everywhere

You may have the impression that this is a particularly early or especially virulent flu season, or that something unusual is afoot.

January 6, 2026 Check out STAT+

Sponsored By

Fred Murphy/CDC via AP Why flu seems to be everywhere — even if 'super flu' is not a thing CDC says H3N2 influenza is causing almost all the illness so far this season, and almost all the H3N2 viruses circulating right now are from subclade K. By Helen Branswell New vaccine schedule adds near- and long-term risks for children, experts warn Pediatricians explain how changes to the childhood vaccine schedule could affect clinic visits, insurance coverage, school requirements, and children's health. By Isabella Cueto STAT+ | Federal appeals court upholds ruling blocking NIH cap on research overhead payments Judges rule the Trump administration's intended cap on research overhead support violated congressional language meant to block such changes By Jonathan Wosen Adobe STAT+ | AI has finally started making drug-like antibodies. When will it revolutionize biopharma? AI can now design drug-like antibodies, but even biotech executives embracing the new tech say traditional wet lab techniques still have a very important role to play. By Brittany Trang Opinion: What I got wrong 33 years ago as a new pediatrician talking to parents about vaccines Former acting CDC Director Richard Besser on how pediatricians need to listen to parents who are worried about vaccines. By Richard Besser With political savvy and outrage over drug prices, advocate David Mitchell was ahead of his time Mitchell created Patients for Affordable Drugs to raise awareness of the increasingly dire circumstances confronting many Americans. By Ed Silverman Mario Tama/Getty Images Opinion: I oversaw the development of the 'hospital at home' CMS waiver. Congress must update the program If Congress wants a permanent national model for a more widespread implementation of hospital at home, it must adapt the program to the current moment. By Lee Fleisher STAT+ | Arrowhead's gene-silencing drugs cut fat in early obesity studies In an early study, patients who took two doses of ARO-INHBE combined with Eli Lilly's Zepbound lost 9.4% of their weight after 16 weeks. By Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser